Copyright
©The Author(s) 2019.
World J Gastroenterol. Oct 7, 2019; 25(37): 5711-5731
Published online Oct 7, 2019. doi: 10.3748/wjg.v25.i37.5711
Published online Oct 7, 2019. doi: 10.3748/wjg.v25.i37.5711
Table 1 Characteristics of 28 included studies.
First author | Year | Country | Study design | Sample size | Conver-sion n (%) | ISGPF | ISGPS | Clavien-Dindo | Quali-ty Scor-es | |
TLPD | OPD | |||||||||
Zimmerman | 2018 | USA | Retrospective analysis | 280 | 6336 | 78 (27.86) | NR | NR | NR | 7a |
Tran | 2016 | USA | Retrospective analysis | 681 | 14893 | NR | NR | NR | NR | 7a |
Tee | 2015 | USA | Retrospective analysis | 113 | 225 | NR | YES | YES | YES | 8a |
Tan | 2015 | China | Retrospective analysis | 30 | 30 | NR | YES | YES | NR | 9a |
Stauffer | 2017 | USA | Retrospective analysis | 58 | 193 | NR | YES | YES | YES | 8a |
Song | 2015 | Korea | Matched case-control study | 97 | 198 | NR | YES | YES | YES | 8a |
Sharpe | 2015 | USA | Retrospective analysis | 384 | 4037 | NR | NR | NR | NR | 7a |
Senthilna-than | 2015 | India | Retrospective analysis | 45 | 118 | NR | NR | NR | NR | 8a |
Poves | 2018 | Spain | RCT | 32 | 29 | 8 (25.00) | YES | YES | YES | 4b |
Palanivelu | 2017 | India | RCT | 32 | 32 | 1 (3.13) | YES | YES | YES | 3b |
Meng | 2018 | China | Retrospective analysis | 58 | 58 | NR | YES | YES | YES | 9a |
Lee | 2018 | Korea | Matched case-control study | 31 | 31 | NR | NR | NR | NR | 9a |
Khaled | 2018 | UK | Matched case-control study | 15 | 15 | 1 (6.67) | YES | YES | YES | 9a |
Kantor | 2017 | USA | Retrospective analysis | 828 | 7385 | NR | NR | NR | NR | 7a |
Hakeem | 2014 | UK | Matched case-control study | 12 | 12 | NR | NR | NR | YES | 9a |
Gerber | 2017 | USA | Retrospective analysis | 52 | 50 | NR | NR | NR | NR | 8a |
Dokmak | 2015 | France | Matched case-control study | 46 | 46 | 3 (6.52) | YES | YES | YES | 9a |
Delitto | 2016 | USA | Retrospective analysis | 52 | 50 | NR | YES | YES | YES | 8a |
Croome | 2014 | USA | Retrospective analysis | 108 | 214 | 7 (6.48) | YES | YES | YES | 8a |
Conrad | 2017 | USA | Retrospective analysis | 40 | 25 | 9 (22.50) | YES | YES | YES | 8a |
Chopinet | 2018 | France | Retrospective analysis | 65 | 290 | NR | YES | YES | YES | 8a |
Chen | 2018 | China | Retrospective analysis | 47 | 55 | NR | YES | YES | YES | 8a |
Chapman | 2018 | USA | Retrospective analysis | 22 | 25 | 0 (0) | YES | YES | YES | 8a |
Chapman | 2018 | USA | Retrospective analysis | 248 | 1520 | 74 (29.84) | NR | NR | NR | 7a |
Asbun | 2012 | USA | Retrospective analysis | 53 | 215 | 9 (15.00) | YES | YES | NR | 8a |
Zureikat | 2011 | USA | Matched case-control study | 14 | 14 | 2 (14.29) | YES | NR | YES | 9a |
Mesleh | 2013 | USA | Retrospective analysis | 75 | 48 | 10 (13.33) | YES | YES | YES | 8a |
Speicher | 2014 | USA | Retrospective analysis | 25 | 84 | NR | YES | NR | NR | 8a |
Table 2 Meta-analysis of intraoperative and perioperative results
Outcome of interest | No. of studies | Sample size | Heterogeneity | Model | Overall effect size | 95%CI of overall effect | P-value | ||
TLPD | OPD | P | I2 | ||||||
Operative time | 11 | 642 | 1129 | < 0.00001 | 99% | R | WMD = 77.92 | 40.89, 114.95 | < 0.0001 |
EBL | 10 | 612 | 1324 | < 0.00001 | 98% | R | WMD = -260.08 | -336.02, -184.14 | < 0.00001 |
Transfusion rate | 12 | 1254 | 15964 | 0.003 | 60% | R | OR = 0.51 | 0.36, 0.72 | 0.0001 |
Overall morbidity | 12 | 1407 | 22126 | 0.10 | 37% | F | OR = 0.82 | 0.73, 0.92 | 0.0008 |
Major morbidity | 16 | 886 | 1704 | 0.05 | 41% | F | OR = 0.88 | 0.70, 1.10 | 0.25 |
POPF | 17 | 954 | 7629 | 0.42 | 3% | F | OR = 0.95 | 0.79, 1.15 | 0.62 |
POPF (grade B/C) | 18 | 942 | 1821 | 0.47 | 0 | F | OR = 0.96 | 0.76, 1.22 | 0.75 |
DGE | 13 | 890 | 7452 | 0.98 | 0 | F | OR = 0.99 | 0.78, 1.24 | 0.90 |
DGE (grade B/C) | 7 | 479 | 994 | 0.60 | 0 | F | OR = 0.63 | 0.45, 0.88 | 0.006 |
PPH | 13 | 771 | 7363 | 0.74 | 0 | F | OR = 1.12 | 0.89, 1.42 | 0.34 |
PPH (grade B/C) | 7 | 454 | 966 | 0.91 | 0 | F | OR = 1.02 | 0.65, 1.60 | 0.95 |
Bile leak | 8 | 289 | 522 | 0.96 | 0 | F | OR = 1.11 | 0.57, 2.16 | 0.76 |
Gastroente-ric anastomosis fistula | 4 | 201 | 423 | 0.77 | 0 | F | OR = 0.62 | 0.16, 2.40 | 0.49 |
Wound infection | 10 | 612 | 7033 | 0.38 | 7% | F | OR = 0.48 | 0.34, 0.67 | < 0.0001 |
Intra-abdominal abscess | 6 | 455 | 6676 | 0.32 | 14% | F | OR = 0.97 | 0.71, 1.31 | 0.82 |
Bowel obstruction | 2 | 73 | 73 | 0.33 | 0 | F | OR = 1.00 | 0.14, 7.31 | 1.00 |
Fluid collection | 3 | 142 | 367 | 0.20 | 37% | F | OR = 1.50 | 0.90, 2.48 | 0.12 |
Pneumonia | 13 | 1489 | 22399 | 0.99 | 0 | F | OR = 0.72 | 0.60, 0.85 | 0.0002 |
Cardiac event | 6 | 1200 | 21877 | 0.75 | 0 | F | OR = 1.04 | 0.82, 1.32 | 0.75 |
Reoperation | 14 | 881 | 7616 | 0.40 | 5% | F | OR = 1.10 | 0.83, 1.47 | 0.51 |
ICU admission | 2 | 171 | 283 | 0.40 | 0 | F | OR = 0.90 | 0.53, 1.54 | 0.71 |
ICU stay | 2 | 65 | 227 | 0.62 | 0 | F | WMD = -2.08 | -2.88, -1.29 | < 0.00001 |
Diet Start Time | 3 | 175 | 284 | <0.0001 | 90% | R | WMD = -1.75 | -3.38, -0.12 | 0.04 |
LOS | 10 | 1544 | 11922 | < 0.00001 | 78% | R | WMD = -3.05 | -3.93, -2.17 | < 0.00001 |
Discharge to a new facility | 4 | 498 | 6826 | 0.74 | 0 | F | OR = 0.55 | 0.39, 0.78 | 0.0008 |
30-d readmission | 10 | 2006 | 19786 | 0.30 | 15% | F | OR = 0.81 | 0.68, 0.95 | 0.010 |
90-d readmission | 4 | 136 | 279 | 0.70 | 0 | F | OR = 1.07 | 0.62, 1.84 | 0.81 |
30-d mortality | 18 | 2870 | 35337 | 0.70 | 0 | F | OR = 1.00 | 0.81, 1.24 | 1.00 |
90-d mortality | 11 | 1273 | 9159 | 0.77 | 0 | F | OR = 0.77 | 0.58, 1.01 | 0.06 |
Table 3 Meta-analysis of oncological outcomes
Outcome of interest | No. of studies | Sample size | Heterogeneity | Model | Overall effect size | 95%CI of overall effect | P-value | ||
TLPD | OPD | P | I2 | ||||||
Tumor size | 10 | 814 | 4782 | < 0.00001 | 85% | R | WMD = -0.32 | -0.58, -0.07 | 0.01 |
RLNs | 12 | 1600 | 12347 | < 0.00001 | 77% | R | WMD = 1.32 | 0.57, 2.06 | 0.0005 |
R0 rate | 19 | 1991 | 14477 | 0.88 | 0 | F | OR = 1.28 | 1.13, 1.44 | 0.0001 |
Time to adjuvant chemotherapy | 2 | 867 | 7526 | 0.39 | 0 | F | WMD = -2.44 | -4.39, -0.49 | 0.01 |
RFS of all malignant tumor patients | |||||||||
1-yr RFS | 2 | 52 | 37 | NA | NA | F | OR = 0.44 | 0.16, 1.23 | 0.12 |
3-yr RFS | 2 | 52 | 37 | 0.22 | 35% | F | OR = 0.53 | 0.19, 1.47 | 0.22 |
5-yr RFS | 2 | 52 | 37 | 0.31 | 4% | F | OR = 0.40 | 0.12, 1.33 | 0.14 |
OS of all malignant tumor patients | |||||||||
1-yr OS | 5 | 412 | 2206 | 0.007 | 72% | R | OR = 0.62 | 0.33, 1.19 | 0.15 |
2-yr OS | 4 | 400 | 2194 | 0.03 | 66% | R | OR = 0.61 | 0.32, 1.17 | 0.14 |
3-yr OS | 5 | 412 | 2206 | 0.08 | 51% | R | OR = 0.80 | 0.40, 1.62 | 0.54 |
4-yr OS | 4 | 400 | 2194 | 0.60 | 0 | F | OR = 0.73 | 0.41, 1.30 | 0.28 |
5-yr OS | 6 | 520 | 2420 | 0.52 | 0 | F | OR = 0.78 | 0.38, 1.59 | 0.49 |
OS of PDAC patients | |||||||||
1-yr OS | 3 | 349 | 1947 | 0.28 | 22% | F | OR = 0.93 | 0.74, 1.18 | 0.57 |
2-yr OS | 3 | 349 | 1947 | 0.21 | 37% | F | OR = 0.93 | 0.70, 1.24 | 0.63 |
3-yr OS | 3 | 349 | 1947 | 0.60 | 0 | F | OR = 0.86 | 0.56, 1.34 | 0.52 |
4-yr OS | 3 | 349 | 1947 | 0.95 | 0 | F | OR = 0.97 | 0.49, 1.92 | 0.94 |
5-yr OS | 3 | 349 | 1947 | 0.27 | 17% | F | OR = 0.65 | 0.19, 2.23 | 0.49 |
OS of periampullary adenocarcinoma patients | |||||||||
1-yr OS | 3 | 349 | 1947 | 0.28 | 22% | F | OR = 0.93 | 0.74, 1.18 | 0.57 |
2-yr OS | 3 | 349 | 1947 | 0.21 | 37% | F | OR = 0.93 | 0.70, 1.24 | 0.63 |
3-yr OS | 3 | 349 | 1947 | 0.60 | 0 | F | OR = 0.86 | 0.56, 1.34 | 0.52 |
4-yr OS | 3 | 349 | 1947 | 0.95 | 0 | F | OR = 0.97 | 0.49, 1.92 | 0.94 |
5-yr OS | 3 | 349 | 1947 | 0.27 | 17% | F | OR = 0.65 | 0.19, 2.23 | 0.49 |
5-yr OS | 6 | 520 | 2420 | 0.52 | 0 | F | OR = 0.78 | 0.38, 1.59 | 0.49 |
Table 4 Results of sensitivity analysis of total laparoscopic pancreaticoduodenectomy vs open pancreaticoduodenectomy
Outcomes of interest | No. of Studies | Sample size | Heterogeneity | Model | Overall effect size | 95%CI of overall effect | P-value | ||
TLPD | OPD | P | I2 | ||||||
Operative time | 10 | 577 | 1064 | < 0.00001 | 98% | R | WMD = 74.66 | 43.71, 105.62 | < 0.00001 |
EBL | 9 | 547 | 1034 | < 0.00001 | 95% | R | WMD = -280.46 | -347.73, -213.19 | < 0.00001 |
Transfusion rate | 10 | 573 | 1071 | 0.15 | 32% | F | OR = 0.45 | 0.35, 0.58 | < 0.00001 |
Overall morbidity | 9 | 381 | 607 | 0.31 | 15% | F | OR = 0.88 | 0.65, 1.18 | 0.38 |
Major morbidity | 15 | 829 | 1414 | 0.49 | 0 | F | OR = 0.75 | 0.59, 0.96 | 0.02 |
POPF | 15 | 617 | 1003 | 0.61 | 0 | F | OR = 0.82 | 0.64, 1.05 | 0.11 |
POPF (grade B/C) | 17 | 877 | 1531 | 0.89 | 0 | F | OR = 0.86 | 0.66, 1.11 | 0.24 |
DGE | 10 | 523 | 801 | 0.93 | 0 | F | OR = 0.93 | 0.64, 1.34 | 0.69 |
DGE (grade B/C) | 7 | 479 | 994 | 0.60 | 0 | F | OR = 0.63 | 0.45, 0.88 | 0.006 |
PPH | 11 | 434 | 737 | 0.84 | 0 | F | OR = 1.48 | 0.93, 2.36 | 0.10 |
PPH (grade B/C) | 7 | 454 | 966 | 0.91 | 0 | F | OR = 1.02 | 0.65, 1.60 | 0.95 |
Bile leak | 7 | 232 | 232 | 0.93 | 0 | F | OR = 1.00 | 0.45, 2.25 | 0.99 |
Gastroente-ric anastomosis fistula | 3 | 136 | 133 | 0.54 | 0 | F | OR = 0.49 | 0.09, 2.73 | 0.42 |
Wound infection | 9 | 332 | 697 | 0.46 | 0 | F | OR = 0.57 | 0.39, 0.84 | 0.005 |
Intra-abdominal abscess | 5 | 175 | 340 | 0.23 | 29% | F | OR = 0.74 | 0.39, 1.38 | 0.34 |
Bowel obstruction | 2 | 73 | 73 | 0.33 | 0 | F | OR = 1.00 | 0.14, 7.31 | 1.00 |
Fluid collection | 2 | 77 | 77 | 0.96 | 0 | F | OR = 0.63 | 0.21, 1.89 | 0.41 |
Pneumonia | 10 | 463 | 880 | 0.99 | 0 | F | OR = 0.79 | 0.54, 1.15 | 0.21 |
Cardiac event | 4 | 239 | 648 | 0.48 | 0 | F | OR = 1.11 | 0.75, 1.62 | 0.61 |
Reoperation | 12 | 544 | 990 | 0.46 | 0 | F | OR = 0.76 | 0.48, 1.21 | 0.25 |
ICU admission | 2 | 171 | 283 | 0.40 | 0 | F | OR = 0.90 | 0.53, 1.54 | 0.71 |
ICU stay | 2 | 65 | 227 | 0.62 | 0 | F | WMD = -2.08 | -2.88, -1.29 | < 0.00001 |
Diet start time | 3 | 175 | 284 | <0.0001 | 90% | R | WMD = -1.75 | -3.38, -0.12 | 0.04 |
LOS | 8 | 332 | 500 | 0.004 | 67% | R | WMD = -3.69 | -4.90, -2.48 | < 0.00001 |
Discharge to a new facility | 3 | 218 | 490 | 0.60 | 0 | F | OR = 0.50 | 0.28, 0.87 | 0.01 |
30-d readmission | 6 | 340 | 508 | 0.77 | 0 | F | OR = 1.04 | 0.68, 1.59 | 0.86 |
90-d readmission | 4 | 136 | 279 | 0.70 | 0 | F | OR = 1.07 | 0.62, 1.84 | 0.81 |
30-d mortality | 12 | 527 | 1271 | 0.76 | 0 | F | OR = 1.26 | 0.59, 2.68 | 0.55 |
90-d mortality | 9 | 312 | 661 | 0.96 | 0 | F | OR = 0.60 | 0.31, 1.17 | 0.14 |
Time to adjuvant chemothe-rapy | 1 | 39 | 141 | NA | NA | F | WMD = -5.50 | -12.71, 1.71 | 0.14 |
Tumor size | 9 | 430 | 745 | 0.0002 | 73% | R | WMD = -0.36 | -0.63, -0.09 | 0.008 |
RLNs | 10 | 388 | 925 | < 0.00001 | 79% | R | WMD = 1.28 | 0.29, 2.27 | 0.01 |
R0 rate | 16 | 605 | 1535 | 0.87 | 0 | F | OR = 1.44 | 1.07, 1.94 | 0.02 |
OS of PDAC | |||||||||
1-yr OS | 2 | 65 | 427 | 0.49 | 0 | F | OR = 0.65 | 0.37, 1.13 | 0.12 |
2-yr OS | 2 | 65 | 427 | 0.74 | 0 | F | OR = 0.54 | 0.27, 1.07 | 0.08 |
3-yr OS | 2 | 65 | 427 | 0.37 | 0 | F | OR = 0.98 | 0.46, 2.10 | 0.96 |
4-yr OS | 2 | 65 | 427 | 0.82 | 0 | F | OR = 1.04 | 0.43, 2.52 | 0.93 |
5-yr OS | 2 | 65 | 427 | 0.27 | 17% | F | OR = 0.65 | 0.19, 2.23 | 0.49 |
OS of periampullary adenocarcinoma patients | |||||||||
1-yr OS | 2 | 23 | 234 | 0.004 | 88% | R | OR = 0.85 | 0.01, 107.31 | 0.95 |
3-yr OS | 2 | 23 | 234 | 0.01 | 84% | R | OR = 0.90 | 0.01, 86.00 | 0.96 |
5-yr OS | 2 | 23 | 234 | 0.26 | 20% | F | OR = 1.57 | 0.43, 5.73 | 0.49 |
- Citation: Zhang H, Lan X, Peng B, Li B. Is total laparoscopic pancreaticoduodenectomy superior to open procedure? A meta-analysis. World J Gastroenterol 2019; 25(37): 5711-5731
- URL: https://www.wjgnet.com/1007-9327/full/v25/i37/5711.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i37.5711